Coalition vice presidents explain the FDAs shortcomings and why U.S. medicines are often in short supply in a new American Affairs Journal article.
CPA advocates for domestic manufacturing of essential generic drugs, personal protective equipment (PPE), and other critical health care products because it is vital for our country’s health security and national security.
COVID-19 showed that in a pandemic, the United States cannot depend on other countries for essential medicines and other medical supplies. Many countries banned exports of them to assure they had enough for their own people.
It is a national security imperative that our country is not dependent on unfriendly nations. At the height of the pandemic, the Chinese Communist Party threatened to withhold essential drugs from America. This threat reveals the inclination by some nations to use medicines as an economic and geopolitical weapon. We must have the capability to manufacture medicines and medical supplies necessary for the country’s public health and survival.
The expert witness testimony made it clear that U.S. labs were treated differently than foreign ones, and despite increases in hiring at the FDA over the years, lawmakers have a lot to be concerned about when it comes to the FDA conducting proper oversight of foreign manufacturing facilities.
According to expert testimony given by the witnesses, the crisis is being fueled by poor manufacturing practices that have led to recalls by foreign drug manufacturers, and the race to the bottom on generic drug prices that make it impossible for American generic drug makers to compete with subsidized competitors in India and China.
New CPA Report: Aurobindo, Largest Generic Drug Provider to U.S. Market, has Substantial Ties to Sanctioned CCP Companies
CPA’s report exposes that “Aurobindo does business with at least four suppliers that have ties to organizations under US sanctions for their connections to China’s military industry.”
The Active Pharmaceutical Ingredient Innovation Center (APIIC), a consortium of biotechnology industry, policy and academic leaders, said in a whitepaper released to the media on Jan. 24, that reshoring the manufacture of essential, life-saving pharmaceuticals was urgently needed.
In Senate hearing: imported generic drugs facing consistent drug shortages need a government incentive program to help labs make life-saving commodity drugs domestically.